Catalent (NYSE:CTLT) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.780-2.970 for the period, compared to the Thomson Reuters consensus estimate of $2.830. The company issued revenue guidance of $3.88 billion-$3.98 billion, compared to the consensus revenue estimate of $3.89 billion.
Several research firms recently commented on CTLT. Royal Bank of Canada increased their target price on shares of Catalent from $125.00 to $137.00 and gave the company an outperform rating in a report on Wednesday, February 3rd. Morgan Stanley increased their target price on shares of Catalent from $115.00 to $135.00 and gave the company an overweight rating in a report on Wednesday, February 3rd. Zacks Investment Research raised shares of Catalent from a hold rating to a buy rating and set a $125.00 target price on the stock in a report on Tuesday, May 4th. UBS Group increased their target price on shares of Catalent from $115.00 to $135.00 and gave the company a buy rating in a report on Wednesday, February 3rd. Finally, Argus raised their price target on shares of Catalent from $130.00 to $140.00 and gave the stock a buy rating in a report on Tuesday, March 2nd. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Catalent currently has an average rating of Buy and an average target price of $125.11.
Shares of CTLT traded down $1.00 during trading hours on Thursday, reaching $100.48. 1,106,569 shares of the company traded hands, compared to its average volume of 1,068,573. The company’s fifty day moving average price is $108.37 and its two-hundred day moving average price is $107.01. The company has a market capitalization of $17.12 billion, a price-to-earnings ratio of 64.00, a price-to-earnings-growth ratio of 2.68 and a beta of 1.50. The company has a quick ratio of 2.14, a current ratio of 2.56 and a debt-to-equity ratio of 0.97. Catalent has a 12 month low of $67.97 and a 12 month high of $127.68.
In related news, CEO John R. Chiminski sold 42,220 shares of Catalent stock in a transaction dated Thursday, March 18th. The shares were sold at an average price of $105.16, for a total transaction of $4,439,855.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Wetteny Joseph sold 5,000 shares of Catalent stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $124.54, for a total transaction of $622,700.00. The disclosure for this sale can be found here. Insiders have sold a total of 70,267 shares of company stock worth $7,473,394 in the last ninety days. Insiders own 1.00% of the company’s stock.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.